@onclive.bsky.social
@tamedoncol.bsky.socialGet ready for #ESMO26 by revisiting the evolving treatment landscape of #SCLC with this review published on #TAMO in 2025.
From current standards to DLL3-targeted therapies, #ADCs and emerging biomarkers.
#Lungcancer
🔗 buff.ly/B2U9VpQ
@Roya_Behrouzi @fblackhall
@icon-plc.bsky.socialOncology biotechs need development strategies that can respond to rapid decisions and scale as programs advance. Meet the ICON Biotech and oncology experts at #ESMO26, booth #8005. Arrange a meeting: https://ow.ly/YOZG50ZTnXt
@oncoalert.bsky.socialThe OncoAlert #ESMO26 PULSE is ready 🇪🇸
As Madrid gets closer, your OncoAlert Network has gathered the faculty who will report live from ESMO and keep you up to date on the science out of Spain.
In the room or following from home, we've got you covered.
✅ Less noise
✅ No nonsense
✅ Just science
@salutedomani.bsky.socialTumore e IA: Insilico Medicine presenterà i primi dati sull’uomo dell’inibitore pan-TEAD ISM6331 a #ESMO26
Insilico Medicine, azienda di ricerca di farmaci basata sull'intelligenza artificiale generativa (IA) in fase clinica, ha ricordato oggi alla comunità oncologica che i dati iniziali della…
@axs-studio.com
@icon-plc.bsky.socialBiomarkers, ctDNA and liquid biopsy are reshaping patient selection and oncology trial design. Meet ICON experts at #ESMO26, booth #8005, to discuss the clinical and operational implications for your program. Arrange a meeting: https://ow.ly/pnPg50ZTnME
@myesmo.bsky.socialThe #ESMOAmbassadors represent expertise across tumour types and oncology disciplines.
Explore their profiles and discover which Ambassadors to follow during #ESMO26.
🔗 https://ow.ly/cyUC50ZOEjF
@onc-rg.bsky.social𝙏𝙝𝙚 2026 𝙀𝙎𝙈𝙊 𝙇𝘽𝘼 𝙇𝙖𝙣𝙙𝙨𝙘𝙖𝙥𝙚: 𝙑𝙞𝙨𝙪𝙖𝙡𝙞𝙯𝙚𝙙.
Which mechanisms are commanding the late-breaker spotlight this year?
#ESMO2026 #ESMO26 #Oncology #NSCLC #SCLC #ADCs #vaccines #ClinicalData #DrugTrials #CompetitiveStrategy
@ipharmaservices.bsky.social@ipharmaservices.bsky.social@ipharmaservices.bsky.socialDati a 5 anni da CARTITUDE-2: Una singola infusione di #Carvykti ha mantenuto il 50% dei pazienti con #mielomamultiplo in recidiva precoce libero da progressione senza terapia di mantenimento (PFS mediana: 60,5 mesi)
www.ipharmacenter.com/post/interna...
#IMS2026 #ESMO26 #Cancro
@aftimosp.bsky.socialWith #ESMO26 in Madrid around the corner, the LBAs list os now available online and in the program!
@myesmo.bsky.social📣 #ESMO26: The late-breaking abstract lineup is taking shape!
Authors & titles are online, and most of the submissions are already there. 30K+ delegates already registered from around the world, so this means new data, new insights and new opportunities to connect.
@onc-rg.bsky.social
@aftimosp.bsky.socialI am thrilled to be part of this group with stellar ⭐️ colleagues and I look forward to interactions and discussions around high quality data at #ESMO26 !
@myesmo.bsky.socialESMO is pleased to announce the #ESMOAmbassadors for #ESMO26.
They will share scientific highlights, expert perspectives and insights on the latest research presented at #ESMO26 across tumour types and disciplines.
🔗Discover the Ambassadors: https://ow.ly/BQ3i50ZOkEv
@myesmo.bsky.social📣 #ESMO26: 4 Keynotes. 1 stage. The next frontier of oncology – CNS disease, AI-driven prediction, radioligand therapy & the role of ageing in cancer.
⏰ Last chance to register at preferential fees - late registration deadline: 16 September 2026
🔗 https://ow.ly/xh2Y50ZLVMY
@myesmo.bsky.social📣 #ESMO26: Join Prof. James Larkin, Scientific Committee Co-Chair, to exchange perspectives, debate emerging evidence, and discuss the future of cancer prevention, diagnosis, and treatment.
⏰ Late registration deadline: 16 September 2026
🔗 https://ow.ly/q9GM50ZJcZh
